The chinolones significantly increased the release of verotoxin2 from clinical VTEC O26 in vitro
Abstract number: 1135_13
Liptakova A., Hikri O., Takacova V., Molokacova M., Siegfried L., Kotulova D.
Verotoxin-producing Escherichia coli (VTEC) cause hemolytic-uremic syndrome (HUS) mostly in children. Children hospitalised at Intensive Care Units are given antibiotics prophylaxis. However, it has been recognized that certain antimicrobial drugs have capacity to enhance the release of verotoxin. We have investigated the influence of antimicrobial drugs used against gram-negative bacteria to verotoxin2-positive clinical VTEC O26 in vitro.
The clinical VTEC strain isolated from 4-year-old child suffering from HUS was incubated with ampicillin/sulbactam, meropenem, cefepime, piperaciline, piperacilline/tazobactam, cefotaxime, ceftazidime, gentamicine, amikacin, ciprofloxacine and trimethoprime/sulfamethoxazole using dilution method. After 2 h and 4 h incubation, the verotoxin was separated and the presence of verotoxin was confirmed by ELISA with monoclonal antibodies against verotoxin2. We used t-test for statistical analysis.
Based on ELISA tests, we have not found any significant increase or decrease of verotoxin release after 2 h incubation. However, after 4 h incubation we have found that ciprofloxacin (p < 0.05) significantly induced the production of verotoxin 2 and verotoxin release from clinical VTEC strain was significantly decreased by meropenem and amikacine (p < 0.05) compared with clinical VTEC strain incubated without antibiotics.
Antimicrobial drugs play role not only as inhibitors of the bacterial growth but some of them can activate the production of important virulence factors. Therefore, it is important not only isolation of VTEC from HUS patients but also detection of the influence of antibiotics used for prophylaxis in hospitals to verotoxin production of isolated strain.
|Session name:||XXIst ISTH Congress|
|Back to top|